MBOT, US59503A2042

Microbot Medical stock gained 2.34 percent on October 6

Published on 10/07/2026 at 03:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A three-year Israel distribution deal opens a new market for Microbot Medical stock. Q2 revenue rose more than 100 percent from the prior quarter, with initial orders anticipated in Q4 2026.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical stock (ISIN US59503A2042) was trading at USD 1.0950 on Nasdaq on October 6, 2026 at 1:11 p.m. EDT, up 2.34 percent from the prior close. The company has also signed a three-year exclusive distribution agreement for its LIBERTY Endovascular Robotic System in Israel, according to GlobeNewswire on October 6, 2026.

Israel adds a commercial channel

Medtechnica Ltd. is authorized to market and sell LIBERTY throughout Israel. The company anticipates initial orders during Q4 2026 after receiving approval from the Israeli Ministry of Health's AMAR Division and registration in the Israeli Medical Device Registry in May 2026.

The agreement gives Microbot Medical an international distribution route while the company continues building its U.S. commercial footprint. LIBERTY is described by GlobeNewswire as a single-use, remotely operated robotic system for peripheral endovascular procedures.

Q2 growth meets a small base

Microbot Medical's 2026 second-quarter revenue increased by more than 100 percent from the prior fiscal quarter, driven by repeat orders, wider use among existing customers and new customers after the LIBERTY full-market release, according to the company's press-release page dated August 11, 2026. The company also reported new customers in the third quarter while expanding into additional states and sites.

The comparison matters because the commercial ramp remains early. Revenue growth from the prior quarter is a positive operating signal, while the Israeli agreement still points to future orders rather than booked sales in the current session.

Stock remains far below its high

Microbot Medical's market capitalization stood at USD 71.9 million on October 6, 2026, and volume reached 1,650,000 shares against a 65-day average of 633,120. The trading volume was 161 percent above that average, while the quote sat 67.3 percent below the 52-week high of USD 3.3500.

The same Nasdaq session showed a range of USD 1.0550 to USD 1.1650, placing the last quoted price inside the day's trading band. For investors, the commercial test is whether the new distribution channel converts the Q4 2026 order outlook into repeat procedures and revenue.

MBOT trades at USD 1.0950

Microbot Medical stock was last at USD 1.0950 on Nasdaq on October 6, 2026 at 1:11 p.m. EDT. Its 52-week range was USD 1.0500 to USD 3.3500, leaving commercialization progress and order conversion as the key operating measures.